Epizyme’s Board of Directors is composed of accomplished leaders from the healthcare industry who bring their experience in science, medicine, business and finance.
- Andrew R. Allen, M.D., Ph.D.
- Ken Bate
- Robert Bazemore
- Grant Bogle
- Kevin T. Conroy
- Michael F. Giordano, M.D.
- Carl Goldfischer, M.D.
- Pablo Legorreta
- David M. Mott – Chairman
- Victoria Richon, Ph.D
Andrew R. Allen, MA BM BCh MRCP PhD, has served as a director since June 2014. Dr. Allen is co-founder and CEO of Gritstone Oncology, a venture-backed next-generation personalized cancer immunotherapy company that formed in mid-2015. Previously he was co-founder and CMO of Clovis Oncology, Inc. Prior to Clovis, he served in the CMO role at Pharmion Corporation (acquired by Celgene in 2008), as Vice President of BioPharma Development and Head of the Oncology Therapeutic Unit for Chiron Corporation (acquired by Novartis in 2005), and as global project head in Abbott Laboratories’ oncology franchise. Previously, Dr. Allen was with the management consulting firm McKinsey & Company, focusing on oncology strategy. He also serves on the board of directors of Revitope Oncology, Inc., and Cell Design Labs, both privately-held biotechnology companies. Dr. Allen qualified in medicine at Oxford University, earned his Ph.D. from the Imperial College of Science, Technology and Medicine in London, and obtained post-graduate internal medicine qualification as a Member of Royal College of Physicians.
Ken Bate has served as a director since December 2014. Mr. Bate is currently an independent consultant in the biotechnology field. From 2009 to 2012, Mr. Bate served as President and Chief Executive Officer of Archemix, Inc., or Archemix, a privately-held biotechnology company. Prior to Archemix, from 2006 to 2009, Mr. Bate served in various positions at NitroMed, Inc., a pharmaceutical company, most recently as President and Chief Executive Officer. From 2002 to 2005, Mr. Bate served as Chief Financial Officer of Millennium Pharmaceuticals, where he headed the commercial organization. Prior to joining Millennium Pharmaceuticals, Mr. Bate co-founded JSB Partners, LLC, a banking and advisory services firm for biopharmaceutical and life sciences companies. From 1990 to 1996, he was with Biogen Inc., a biotechnology company, first as their Chief Financial Officer, and then as head of the commercial organization responsible for launching the multiple sclerosis business. Mr. Bate serves on the board of directors of four other public biopharmaceutical companies, AVEO Pharmaceuticals, Inc., BioMarin Pharmaceuticals, Inc., Genocea Biosciences, Inc. and Cubist Pharmaceuticals, Inc., where he was the chairman of the board of directors. Mr. Bate received a B.A. in chemistry from Williams College and an M.B.A. from the Wharton School of the University of Pennsylvania.
Robert Bazemore has served as our President and Chief Executive Officer since September 2015. Prior to joining Epizyme, Mr. Bazemore served as Chief Operating Officer of Synageva through its acquisition in July 2015. Prior to that, Mr. Bazemore was President of Janssen Biotech, part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Mr. Bazemore began his career at Johnson & Johnson in 2002, and held numerous senior commercial positions, including leading the worldwide immunology portfolio strategy and the launches of multiple new products and indications. Prior to Johnson & Johnson, Mr. Bazemore worked at Merck & Co., Inc. for eleven years in roles of increasing responsibility. Robert received a B.S. in Biochemistry from the University of Georgia.
Grant Bogle has served on the Epizyme board of directors since September 2019. Since 2015, he has served as senior vice president and chief commercial officer of TESARO, where he oversaw the build-up of the US commercial organization and led the launch of two products, including ZEJULA® (niraparib) for ovarian cancer in the US. Prior to TESARO, Mr. Bogle served as senior vice president of pharmaceutical and biotech solutions at McKesson Specialty Health (formerly US Oncology), where he led numerous businesses that supported oncology-focused companies to engage, educate and support oncologists and patients to access and appropriately utilize their medications. These businesses included data and informatics, health economics and outcomes research, reimbursement hub services and the US Oncology clinical research business units. Before that, he was senior vice president of sales and marketing at Millennium Pharmaceuticals, leading the commercialization of VELCADE® (bortezomib). Earlier in his career, Mr. Bogle held various senior commercial roles with ViaCell, Inc., Roche Pharmaceuticals, Knoll Pharmaceuticals and DuPont Pharmaceuticals. He began his career at American Critical Care, a division of American Hospital Supply Corporation. Mr. Bogle holds a B.A. in economics from Dartmouth College and an MBA from Columbia University’s Columbia School of Business.
Kevin T. Conroy has served as a director since February 2017. Mr. Conroy has served in the roles of Chairman, President and Chief Executive Officer of Exact Sciences since April 2009. In 2004, he joined Third Wave Technology as General Counsel. From 2005 to July of 2008, Mr. Conroy served as Third Wave’s President and Chief Executive Officer until their acquisition by Hologic. Prior to joining Third Wave, Mr. Conroy served as Intellectual Property counsel at GE Healthcare, and as Chief Operating Officer of two early stage, venture-backed technology companies in Northern California. Prior to those positions, he was an Intellectual Property Litigator at two Chicago law firms: McDermott Will & Emery; and Pattishall, McAuliffe, Newbury, Hilliard and Geraldson, where he was a partner. Mr. Conroy earned a Bachelor of Science degree in electrical engineering at Michigan State University and Law degree from the University of Michigan.
Michael F. Giordano, M.D., has served as a director since March 2018 and is currently serving as a clinical advisor to the company. Prior to this, Dr. Giordano was senior vice president and head of development, oncology and immuno-oncology for Bristol-Myers Squibb (BMS). In this role, he was responsible for the development strategy for this therapeutic area, as well as for the direction of eight teams working on innovative medicines to improve the standard of care for patients, including Opdivo®, Yervoy®, Empliciti™, Ixempra®, and Sprycel®. He previously held positions of increasing responsibility within the BMS research and development organization, leading the development of more than a dozen molecules in the United States, Europe and Asia. Before joining BMS, he served as assistant professor of medicine and founding director of the Cornell Clinical Trials Unit, a National Institutes of Health and Industry-supported AIDS clinical trials center at New York Hospital-Cornell University Medical Center. He earned his M.D. and completed his residency and fellowship training at New York Presbyterian-Weill Cornell Medical Center, and received his B.A. in natural sciences from The Johns Hopkins University.
Carl Goldfischer, M.D. has served as a director since September 2009. Dr. Goldfischer has served as an Investment Partner and Managing Director of Bay City Capital LLC, as a member of the board of directors and executive committee, and has been with the firm since January 2000. Prior to joining Bay City Capital, Dr. Goldfischer was Chief Financial Officer of ImClone Systems Incorporated, a biopharmaceutical company, and since 2004, Dr. Goldfischer has served on the board of directors of EnteroMedics Inc., a publicly traded medical device company. He has previously served on the board of directors of two other publicly traded companies, MAP Pharmaceuticals, Inc., from 2004 to 2011, and Poniard Pharmaceuticals, Inc., from 2000 to 2012. Dr. Goldfischer received a B.A. from Sarah Lawrence College and an M.D. with honors in Scientific Research from Albert Einstein College of Medicine.
Pablo Legorreta is the Founder and Chief Executive of Royalty Pharma. Mr. Legorreta has over 20 years of experience investing in pharmaceutical royalties, and building and managing a rapidly growing life sciences investment company that is today one of the largest dedicated life sciences investors in the world. Prior to founding Royalty Pharma in 1996, Mr. Legorreta was an investment banker at Lazard Frères in Paris and New York. Mr. Legorreta is also a Co-Founder of Pharmakon Advisors, a leading provider of debt capital to the life sciences industry. Mr. Legorreta serves on the Board of Governors of the New York Academy of Sciences, as well as the Boards of Trustees of Rockefeller University, Brown University, the Hospital for Special Surgery, Pasteur Foundation (the U.S. affiliate of the French Institute Pasteur), Open Medical Institute and Park Avenue Armory. Mr. Legorreta is the Founder and Chairman of Alianza Médica para la Salud, a non-profit dedicated to enhancing the quality of health care in Latin America by providing doctors and healthcare providers with continued education opportunities. Mr. Legorreta has a degree in industrial engineering from Universidad Iberoamericana in Mexico City.
David M. Mott has served as a director since December 2009 and is a private investor through Mott Family Capital. From September 2008 to February 2020, Mr. Mott was general partner at New Enterprise Associates (“NEA”) and led the healthcare investing practice. NEA is among the largest venture capital firms in the world and invests across all stages in healthcare and technology. At NEA, Mr. Mott’s personal investing practice was primarily focused on biopharmaceuticals. Prior to joining NEA, Mr. Mott was president and chief executive officer of biotechnology company MedImmune. He joined MedImmune in 1992 and served in various roles, including president and chief executive officer from October 2000 through July 2008 and previously chief financial officer and president and chief operating officer. Mr. Mott led the sale of MedImmune to AstraZeneca in June 2007 for $15.6 billion. Earlier in his career, he was a vice president in healthcare investment banking at Smith Barney, Harris Upham & Co., Inc. Across his career, as chairman, chief executive officer, board member, general partner or operating executive, Mr. Mott has been involved in over $40 billion in corporate acquisitions, fundraising, partnerships and other capital formation. He has been involved in more than 35 initial public offerings or corporate acquisitions, in bringing over a dozen new drugs through development to commercialization, and has served on 25 corporate boards. Mr. Mott is currently Chairman of several public biotechnology companies: Adaptimmune (ADAP), Ardelyx (ARDX), Epizyme (EPZM), Imara (IMRX), Mersana (MRSN), and serves on the board of directors of Novavax (NVAX). Mr. Mott earned a B.A. from Dartmouth College.
Victoria Richon, Ph.D. has served on the board of directors since September 2019. Dr. Richon currently serves as the President and Chief Executive Officer of Ribon Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of first-in-class therapeutics targeting novel enzyme families activated under cellular stress conditions. Prior to Ribon, she was vice president, global head of discovery and early development at Sanofi Oncology in Cambridge, Mass., where she was responsible for overseeing the discovery research and translational medicine of drug candidates emerging from Sanofi’s drug discovery oncology projects. Dr. Richon served as vice president of biological sciences at Epizyme from 2008 to 2012 and played a key role in bringing forward two first-in-class agents from initiation of discovery to clinical trials, including tazemetostat. Before her tenure at Epizyme, she was senior director and department head of cancer biology and therapeutics at Merck & Co., Inc., and before that, was a co-founder at Aton Pharma, Inc. Dr. Richon began her scientific career as a postdoctoral fellow in the Department of Cell Biology at Memorial Sloan-Kettering Cancer Center and is an author on more than 100 peer-reviewed publications. She received her B.A. in chemistry from the University of Vermont and her Ph.D. in biochemistry from the University of Nebraska Medical Center Eppley Institute for Research in Cancer and Allied Diseases.